Yazar "Kaplan, Mehmet A." seçeneğine göre listele
Listeleniyor 1 - 11 / 11
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Clinical characteristics of gastrointestinal stromal tumors in southeast region of Turkey(Oxford Univ Press, 2006) Cil, Timucin; Altintas, Abdullah; Kaplan, Mehmet A.; Ayyildiz, Orhan; Sayar, Suleyman; Akgun, Yilmaz; Isikdogan, Abdurrahman[Abstract Not Available]Öğe Clinical outcome of patients with hairy cell leukemia(Oxford Univ Press, 2006) Altintas, Abdullah; Cil, Timucin; Ayyildiz, Orhan; Atay, Ahmet E.; Kaplan, Mehmet A.; Isikdogan, Abdurrahman; Muftuoglu, Ekrem[Abstract Not Available]Öğe Differentiation of Tuberculous Peritonitis from Peritonitis Carcinomatosa without Surgical Intervention(Medknow Publications & Media Pvt Ltd, 2011) Kaya, Muhsin; Kaplan, Mehmet A.; Isikdogan, Abdurrahman; Celik, YusufBackground/Aim: Ascites of tuberculous peritonitis (TBP) is an exudative type and may well be misdiagnosed as carcinomatous peritonitis, especially in the elderly. The aim of this study was to identify independent predictors that can differentiate TBP from peritonitis carcinomatosa without surgical intervention. Patients and Methods: This prospective cohort study was performed on 75 subjects in the following groups: TBP (n=27) (TBP group), ovarian cancer complicated with ascites (n=24) (Ov Ca group), and gastric cancer complicated with ascites (n=24) (Ga Ca group). The frequency of clinical symptoms, laboratory parameters, and serum tumor markers levels were compared. Results: In univariate analysis; fever, night sweats, and abdominal pain were significantly more frequent in the TBP group compared to those in the Ov Ca group (P < 0.001, P < 0.001, and P = 0.035, respectively) and the Ga Ca group (P < 0.001, P < 0.001, and P = 0.015, respectively). Serum CA 19-9 and carcino embryonic antigen (CEA) levels were significantly lower in the TBP and Ov Ca group compared to the Ga Ca group (P < 0.001 and P < 0.001, respectively). Elevated serum CA 125 level was found in all patients with TBP and Ov Ca and in 86.6% of patients with Ga Ca. In the multivariate analysis, presence of fever (P < 0.001), night sweats (P < 0.001), age under 40 years (P = 0.008), and normal serum CA 19-9 level (P = 0.044) were independent predictor of diagnosis of TBP. Conclusion: The presence of fever, elevated serum CA 125 level, normal serum CA 19-9, and CEA associated with lymphocyte predominant benign ascites may establish the diagnosis of TBP.Öğe Hepatitis C virus in patients with non-Hodgkin's lymphoma in southeastern region of Turkey(Elsevier, 2006) Altintas, Abdullah; Cil, Timucin; Kaplan, Mehmet A.; Atay, Ahmet E.; Isikdogan, Abdurrahman; Ayyildiz, Orhan; Muftuoglu, Ekrem[Abstract Not Available]Öğe Hodgkin ve non-Hodgkin lenfoma olgularında hepatit B enfeksiyonu ve klinik önemi(2007) Yılmaz, Şerif; Altıntaş, Abdullah; Ayyıldız, Mehmet Orhan; Bayan, Kadim; Danış, Ramazan; Kaplan, Mehmet A.; Çil, TimuçinHepatotropik bir virüs olan hepatit B virüsü (HBV) lenfoid hücrelerde de çoğalma potansiyeline sahiptir. Bu durum HBV enfeksiyonu ile lenfoma arasındaki potansiyel ilişkiyi araştırmaya yöneltmiştir. Biz bu çalışmada HBV enfeksiyonunun nisbeten yüksek olduğu Güneydoğu Anadolu bölgesinde Hodgkin lenfoma (HL) ve non-Hodgkin lenfoma (NHL) olgularımızda HBsAg ve AntiHBs sıklığını retrospektif olarak araştırdık. Ocak 1995 ile Aralık 2005 tarihleri arasında 203’ü NHL (%73.6), 73’ü (%26.4) HL tanılı toplam 276 hasta dahil edildi. Toplam 40 hastada HBsAg pozitif saptandı (%14.5). Bu olguların 12 tanesi HL (%16.4), 28’i NHL (%13.7) gurubundaydı. AntiHBs 123 vakada (%44.5) pozitif bulundu [29 (%39.7) HL ve 94 (%46.3 NHL] . Son iki yılda 11 lenfoma olgumuz lamivudin proflaksisi almıştır. Bu olgulardan 10’unda viral reaktivasyon bulguları izlenmezken, diffüz büyük hücreli NHL tanılı lamivudin proflaksisi alan bir hastada viral reaktivasyon gelişti. Profilaksi almamış olan bir HL olgumuzda da Anti- HBc IgM pozitifliği ve transaminaz yüksekliğiyle karakterize HBV reaktivasyonu gözlendi. Bizim çalışmamızda lenfoma olgularında HBsAg sıklığı genel popülasyona oranla daha yüksek bulunmasına karşın, HBV ile HL ve NHL’nin olası etyolojik ilişkisini aydınlatmak amacıyla daha geniş prospektif çalışmalar yapılmalıdır. HBV taşıyıcılarında kemoterapi uygulaması öncesinde lamivudin proflaksisi başlanmalı ve kemoterapi bitiminden sonra en az bir yıl devam edilmelidir.Öğe Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience(Karger, 2013) Cetin, Bulent; Benekli, Mustafa; Dane, Faysal; Boruban, Cem; Gumus, Mahmut; Oksuzoglu, Berna; Kaplan, Mehmet A.Background: The efficacy and safety of the lapatinib and capecitabine combination remain elusive in elderly patients with metastatic breast cancer (MBC), who progress after trastuzumab-based therapy. Patients and Methods: A total of 26 patients with HER2-positive MBC were included in this retrospective multicenter study. Median age was 69 years (range 65-82 years). All patients were treated with the combination of lapatinib (1,250 mg/day, continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Data on demographics, clinical outcome, and toxicity were collected for descriptive analyses. Results: The median follow-up was 10 months (range 2-31 months). An overall response rate of 33.4% was achieved, including 1 complete response (3.8%), and 8 partial responses (30.8%). Median progression-free survival was 7 months (95% confidence interval (CI) 5-8), and the median overall survival was 15 months (95% CI 11-19). Most common side effects were fatigue (53.8%), diarrhea (46%), vomiting (36.3%), hand-foot syndrome (34.5%), and anorexia (34.6%). Grade 3-4 toxicities were identified as hand-foot syndrome (3.8%), diarrhea (7.6%), and fatigue (11.5%). There were no symptomatic cardiac events. Conclusion: Lapatinib and capecitabine combination therapy was effective and well tolerated in elderly patients with MBC, who had progressive disease after trastuzunnab-based therapy.Öğe Prognostic factors affecting local recurrence and systemic metastasis for patients with early breast cancer(Oxford Univ Press, 2006) Cil, Timucin; Isikdogan, Abdurrahman; Altintas, Abdullah; Sayar, Suleyman; Kaplan, Mehmet A.; Buyukbayram, Huseyin[Abstract Not Available]Öğe Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy(Sage Publications Ltd, 2018) Yildiz, Ibrahim; Bilici, Ahmet; Karadurmus, Nuri; Ozer, Leyla; Tural, Deniz; Kaplan, Mehmet A.; Akman, TulayBackground: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and methods: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. Results: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months; p = 0.001), histological subtype (non-CC; p<0.05) and number of BMs (>2; p<0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy. Conclusions: The time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months), a non-CC histological subtype, and a greater number of BMs (>2) were independent risk factors for a poor prognosis.Öğe Results of imatinib mesylate therapy in chronic myeloid leukemia(Elsevier, 2006) Altintas, Abdullah; Cil, Timucin; Ayyildiz, Orhan; Kaplan, Mehmet A.; Isikdogan, Abdurrahman; Muftuoglu, Ekrem; Atay, Ahmet E.[Abstract Not Available]Öğe Successful initial treatment with caspofungin alone for hepatosplenic candidiasis in a patient with acute myeloblastic leukemia(Saudi Med J, 2006) Altintas, Abdullah; Ayyildiz, Orhan; Isikdogan, Abdurrahman; Atay, Engin; Kaplan, Mehmet A.[Abstract Not Available]Öğe Thalidomide-associated thrombosis in multiple myeloma(Elsevier, 2006) Altintas, Abdullah; Cil, Timucin; Ayyildiz, Orhan; Kaplan, Mehmet A.; Atay, Ahmet E.; Isikdogan, Abdurrahman; Muftuoglu, Ekrem[Abstract Not Available]
